FibroGen Inc. (NASDAQ:FGEN) dropped 3.3% during trading on Tuesday . The company traded as low as $18.50 and last traded at $18.61, with a volume of 181,720 shares. The stock had previously closed at $19.25.

FGEN has been the subject of a number of research reports. Credit Suisse Group AG restated a “buy” rating and set a $37.00 price objective on shares of FibroGen in a research report on Tuesday, August 9th. Zacks Investment Research upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Tuesday, May 10th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $33.25.

The stock’s market capitalization is $1.15 billion. The stock’s 50 day moving average is $18.02 and its 200 day moving average is $18.30.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.36 by $0.01. Equities research analysts anticipate that FibroGen Inc. will post ($1.24) earnings per share for the current year.

In other news, CEO Thomas B. Neff sold 37,798 shares of the stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $18.38, for a total transaction of $694,727.24. Following the completion of the sale, the chief executive officer now directly owns 3,413,255 shares in the company, valued at $62,735,626.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Thomas B. Neff sold 27,000 shares of the stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $18.99, for a total transaction of $512,730.00. Following the sale, the chief executive officer now owns 3,507,164 shares of the company’s stock, valued at $66,601,044.36. The disclosure for this sale can be found here.

Several hedge funds have recently bought and sold shares of FGEN. Rhumbline Advisers raised its stake in FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 3,675 shares in the last quarter. Swiss National Bank raised its stake in FibroGen by 1.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the biopharmaceutical company’s stock worth $1,932,000 after buying an additional 1,100 shares in the last quarter. Cornerstone Capital Management Holdings LLC. purchased a new stake in FibroGen during the fourth quarter worth $3,067,000. Finally, California Public Employees Retirement System purchased a new stake in FibroGen during the fourth quarter worth $3,397,000.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.